Do analysts prefer SPRO or SLN?

Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 429.36%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Silence Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Does the media prefer SPRO or SLN?

In the previous week, Spero Therapeutics had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Silence Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Silence Therapeutics' score of -0.72 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend CABA or SPRO?

Cabaletta Bio currently has a consensus price target of $15.50, suggesting a potential upside of 385.89%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor CABA or SPRO?

In the previous week, Spero Therapeutics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.95 beat Spero Therapeutics' score of 0.30 indicating that Cabaletta Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cabaletta Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend OVID or SPRO?

Ovid Therapeutics presently has a consensus target price of $5.13, suggesting a potential upside of 90.52%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ovid Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer NGNE or SPRO?

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 140.05%. Given Neurogene's stronger consensus rating and higher probable upside, equities analysts plainly believe Neurogene is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.00 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor NGNE or SPRO?

In the previous week, Neurogene had 8 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for Neurogene and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Neurogene's score of 0.11 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer VALN or SPRO?

Valneva presently has a consensus target price of $11.98, indicating a potential upside of 129.41%. Given Valneva's stronger consensus rating and higher possible upside, equities analysts plainly believe Valneva is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is VALN or SPRO more profitable?

Spero Therapeutics has a net margin of 24.90% compared to Valneva's net margin of -88.87%. Spero Therapeutics' return on equity of 35.58% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -88.87% -107.63% -33.02% Spero Therapeutics 24.90% 35.58% 24.95%

Does the media prefer VALN or SPRO?

In the previous week, Spero Therapeutics had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Valneva. Spero Therapeutics' average media sentiment score of 0.30 beat Valneva's score of 0.07 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spero Therapeutics (SPRO) Competitors

$2.20 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.15 -0.05 (-2.05%)

As of 07/2/2026 07:29 PM Eastern

Compare

SPRO vs. SLN, CABA, OVID, NGNE, and VALN

Should you buy Spero Therapeutics stock or one of its competitors? MarketBeat compares Spero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spero Therapeutics include Silence Therapeutics (SLN), Cabaletta Bio (CABA), Ovid Therapeutics (OVID), Neurogene (NGNE), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.

How does Spero Therapeutics compare to Silence Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Spero Therapeutics has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.91	$8.57M	$0.24	9.17
Silence Therapeutics	$560K	876.47	-$88.61M	-$1.59	N/A

Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 429.36%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Spero Therapeutics has a net margin of 24.90% compared to Silence Therapeutics' net margin of -8,943.86%. Spero Therapeutics' return on equity of 35.58% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

In the previous week, Spero Therapeutics had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Silence Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Silence Therapeutics' score of -0.72 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Spero Therapeutics beats Silence Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Cabaletta Bio?

Cabaletta Bio (NASDAQ:CABA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Cabaletta Bio currently has a consensus price target of $15.50, suggesting a potential upside of 385.89%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cabaletta Bio has a beta of 3.26, indicating that its share price is 226% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Cabaletta Bio. Cabaletta Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Spero Therapeutics	$66.80M	1.91	$8.57M	$0.24	9.17

Spero Therapeutics has a net margin of 24.90% compared to Cabaletta Bio's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Spero Therapeutics	24.90%	35.58%	24.95%

25.6% of Spero Therapeutics shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Spero Therapeutics had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Cabaletta Bio. Cabaletta Bio's average media sentiment score of 0.95 beat Spero Therapeutics' score of 0.30 indicating that Cabaletta Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spero Therapeutics beats Cabaletta Bio on 9 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Ovid Therapeutics?

Ovid Therapeutics (NASDAQ:OVID) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Spero Therapeutics had 2 more articles in the media than Ovid Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Ovid Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Ovid Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ovid Therapeutics	Neutral
Spero Therapeutics	Neutral

72.2% of Ovid Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 7.0% of Ovid Therapeutics shares are held by insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spero Therapeutics has higher revenue and earnings than Ovid Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ovid Therapeutics	$7.25M	69.25	-$17.41M	-$0.29	N/A
Spero Therapeutics	$66.80M	1.91	$8.57M	$0.24	9.17

Ovid Therapeutics has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Ovid Therapeutics presently has a consensus target price of $5.13, suggesting a potential upside of 90.52%. Given Ovid Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ovid Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has a net margin of 24.90% compared to Ovid Therapeutics' net margin of -240.11%. Spero Therapeutics' return on equity of 35.58% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ovid Therapeutics	-240.11%	-22.51%	-18.67%
Spero Therapeutics	24.90%	35.58%	24.95%

Summary

Spero Therapeutics beats Ovid Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Neurogene?

Neurogene (NASDAQ:NGNE) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 140.05%. Given Neurogene's stronger consensus rating and higher probable upside, equities analysts plainly believe Neurogene is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Neurogene has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	600.40	-$90.35M	-$4.55	N/A
Spero Therapeutics	$66.80M	1.91	$8.57M	$0.24	9.17

Spero Therapeutics has a net margin of 24.90% compared to Neurogene's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Spero Therapeutics	24.90%	35.58%	24.95%

52.4% of Neurogene shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Neurogene had 8 more articles in the media than Spero Therapeutics. MarketBeat recorded 10 mentions for Neurogene and 2 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Neurogene's score of 0.11 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neurogene beats Spero Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Spero Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Spero Therapeutics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.51	-$130.33M	-$1.87	N/A
Spero Therapeutics	$66.80M	1.91	$8.57M	$0.24	9.17

Spero Therapeutics has a net margin of 24.90% compared to Valneva's net margin of -88.87%. Spero Therapeutics' return on equity of 35.58% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Spero Therapeutics	24.90%	35.58%	24.95%

In the previous week, Spero Therapeutics had 1 more articles in the media than Valneva. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Valneva. Spero Therapeutics' average media sentiment score of 0.30 beat Valneva's score of 0.07 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva presently has a consensus target price of $11.98, indicating a potential upside of 129.41%. Given Valneva's stronger consensus rating and higher possible upside, equities analysts plainly believe Valneva is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Valneva has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Spero Therapeutics beats Valneva on 9 of the 16 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRO vs. The Competition

Export

Metric	Spero Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$127.38M	$3.76B	$7.18B	$12.46B
Dividend Yield	N/A	2.16%	2.67%	6.50%
P/E Ratio	9.17	21.43	28.02	24.70
Price / Sales	1.91	324.82	533.82	98.68
Price / Cash	14.46	147.12	49.26	57.09
Price / Book	2.10	8.66	10.96	6.46
Net Income	$8.57M	$23.81M	$3.57B	$337.01M
7 Day Performance	-2.65%	3.39%	2.10%	1.70%
1 Month Performance	-26.17%	6.15%	2.78%	0.68%
1 Year Performance	-24.40%	62.61%	33.35%	23.94%

Spero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRO Spero Therapeutics	1.4081 of 5 stars	$2.20 flat	N/A	-24.4%	$127.38M	$66.80M	9.17	150
SLN Silence Therapeutics	2.4391 of 5 stars	$10.86 +0.6%	$55.00 +406.6%	+87.5%	$514.11M	$839K	N/A	100	Gap Up
CABA Cabaletta Bio	2.7358 of 5 stars	$3.14 +0.8%	$15.50 +394.4%	+98.6%	$511.16M	N/A	N/A	50
OVID Ovid Therapeutics	1.9607 of 5 stars	$2.70 -0.9%	$5.13 +90.2%	+682.0%	$503.00M	$7.25M	N/A	60
NGNE Neurogene	2.9535 of 5 stars	$31.68 -1.9%	$84.83 +167.8%	+76.3%	$501.40M	N/A	N/A	90	News Coverage Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spero Therapeutics (SPRO) Competitors

SPRO vs. SLN, CABA, OVID, NGNE, and VALN

How does Spero Therapeutics compare to Silence Therapeutics?

Summary

How does Spero Therapeutics compare to Cabaletta Bio?

Summary

How does Spero Therapeutics compare to Ovid Therapeutics?

Summary

How does Spero Therapeutics compare to Neurogene?

Summary

How does Spero Therapeutics compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spero Therapeutics (SPRO) Competitors

SPRO vs. SLN, CABA, OVID, NGNE, and VALN

How does Spero Therapeutics compare to Silence Therapeutics?

Which has stronger valuation & earnings, SPRO or SLN?

Which has more risk & volatility, SPRO or SLN?

Do analysts prefer SPRO or SLN?

Is SPRO or SLN more profitable?

Does the media prefer SPRO or SLN?

Do insiders and institutionals have more ownership in SPRO or SLN?

Summary

How does Spero Therapeutics compare to Cabaletta Bio?

Do analysts recommend CABA or SPRO?

Which has more volatility & risk, CABA or SPRO?

Which has preferable earnings and valuation, CABA or SPRO?

Is CABA or SPRO more profitable?

Do institutionals and insiders have more ownership in CABA or SPRO?

Does the media favor CABA or SPRO?

Summary

How does Spero Therapeutics compare to Ovid Therapeutics?

Does the media favor OVID or SPRO?

Do institutionals & insiders have more ownership in OVID or SPRO?

Which has stronger valuation and earnings, OVID or SPRO?

Which has more risk and volatility, OVID or SPRO?

Do analysts recommend OVID or SPRO?

Is OVID or SPRO more profitable?

Summary

How does Spero Therapeutics compare to Neurogene?

Do analysts prefer NGNE or SPRO?

Which has more volatility and risk, NGNE or SPRO?

Which has better earnings & valuation, NGNE or SPRO?

Is NGNE or SPRO more profitable?

Do insiders & institutionals have more ownership in NGNE or SPRO?

Does the media favor NGNE or SPRO?

Summary

How does Spero Therapeutics compare to Valneva?

Which has higher earnings and valuation, VALN or SPRO?

Is VALN or SPRO more profitable?

Does the media prefer VALN or SPRO?

Do analysts prefer VALN or SPRO?

Which has more volatility and risk, VALN or SPRO?

Do insiders & institutionals have more ownership in VALN or SPRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools